Medication-related osteonecrosis of the jaws (MRONJ) review: what Irish dentists need to know, from international guidelines to current controversies
dc.contributor.author | Cooney, Maeve | |
dc.date.accessioned | 2018-10-11T10:06:47Z | |
dc.date.available | 2018-10-11T10:06:47Z | |
dc.date.issued | 2018-09 | |
dc.identifier.uri | http://hdl.handle.net/10147/623854 | |
dc.description | Medication-related osteonecrosis of the jaws (MRONJ) is a potentially severe adverse drug reaction, resulting in progressive bone destruction of the jaws. MRONJ is associated with two classes of therapeutic drugs: antiresorptive and anti-angiogenic agents. There are several hypotheses that attempt to explain the aetiology of the process and its unique localisation to the jaws. Dental screening and appropriate treatment are fundamental to reduce the risk of osteonecrosis before patients begin taking these medications. The treatment of MRONJ often presents great difficulty and an optimal therapy strategy is yet to be established. For this reason, prevention occupies a pivotal role in the management of these patients. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Irish Dental Association | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
dc.subject | DENTAL HEALTH | en_US |
dc.title | Medication-related osteonecrosis of the jaws (MRONJ) review: what Irish dentists need to know, from international guidelines to current controversies | en_US |
dc.type | Article | en_US |
dc.identifier.journal | Irish Dental Association | en_US |
refterms.dateFOA | 2018-10-11T10:06:48Z |